Enrique Morales-Avila

Dr. Enrique Morales-Avila

Universidad Autónoma del Estado de México, Toluca, México, Mexico

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
EMEnrique Morales-Avila
Enrique Morales-Avila
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García
LLLuis M. De León-Rodríguez
Luis M. De León-Rodríguez
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
LGLeobardo Manuel Gómez-Oliván
Leobardo Manuel Gómez-Oliván

1 March 2014 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
AVAndrea Vilchis-Juárez
Andrea Vilchis-Juárez
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
EMEnrique Morales-Avila
Enrique Morales-Avila
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García
LGLeobardo Manuel Gómez-Oliván
Leobardo Manuel Gómez-Oliván
Peptides based on the cyclic Arg-Gly-Asp (RGD) sequence have been designed to antagonize the function of alpha(v)beta(3) integrin, thereby inhibiting angiogenesis. The conjugation of RGD peptides to radiolabeled gold nanoparticles (AuNP) produces biocompatible and stable multimeric systems with target-specific molecular recognition. The aim of this research was to evaluate the therapeutic response of 177Lu-AuNP-RGD in athymic mice bearing alpha(v)beta(3)-integrin-positive C6 gliomas and compare it with that of 177Lu-AuNP or 177Lu-RGD. The radiation absorbed dose, metabolic activity (SUV, [18F]fluor-deoxy-glucose-microPET/CT), histological characteristics and VEGF gene expression (by real-time polymerase chain reaction) in tumor tissues following treatment with 177Lu-AuNP-RGD, 177Lu-AuNP or 177Lu-RGD were assessed. Of the radiopharmaceuticals evaluated, 1177Lu-AuNP-RGD delivered the highest tumor radiation absorbed dose (63.8 +/- 7.9 Gy). These results correlated with the observed therapeutic response, in which 177Lu-AuNP-RGD significantly (p < 0.05) induced less tumor progression, less tumor metabolic activity, fewer intratumoral vessels and less VEGF gene expression than the other radiopharmaceuticals, a consequence of high tumor retention and a combination of molecular targeting therapy (multimeric RGD system) and radiotherapy (177Lu). There was a low uptake in non-target organs and no induction of renal toxicity. 177Lu-labeled gold nanoparticles conjugated to cyclo-RGDfK(C) demonstrate properties suitable for use as an agent for molecular targeting radiotherapy.

1 October 2019 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
RTR. Maydelid Trujillo-Nolasco
R. Maydelid Trujillo-Nolasco
EMEnrique Morales-Avila
Enrique Morales-Avila
BOBlanca E. Ocampo-García
Blanca E. Ocampo-García
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
BGBrenda V. Gibbens-Bandala
Brenda V. Gibbens-Bandala
KIKeila Isaac-Olive
Keila Isaac-Olive

1 January 2011 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García
FRFlor de M. Ramírez
Flor de M. Ramírez
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
LLLuis M. De León-Rodríguez
Luis M. De León-Rodríguez
CSClara Leticia Santos-Cuevas
Clara Leticia Santos-Cuevas
MCMarco A. Camacho-López
Marco A. Camacho-López

1 January 2017 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
EMEnrique Morales-Avila
Enrique Morales-Avila
Guillermina Ferro-FloresGuillermina Ferro-Flores
Guillermina Ferro-Flores
Blanca Ocampo-GarcíaBlanca Ocampo-García
Blanca Ocampo-García
GTGustavo Lopez Tellez
Gustavo Lopez Tellez
JLJohnny López-Ortega
Johnny López-Ortega
DSDiego Sánchez-Padilla
Diego Sánchez-Padilla
Recent studies have demonstrated that drug antimicrobial activity is enhanced when metallic nanoparticles are used as an inorganic support, obtaining synergic effects against microorganisms. The cationic antimicrobial peptide ubiquicidin 29–41 (UBI) has demonstrated high affinity and sensitivity towards fungal and bacterial infections. The aim of this research was to prepare and evaluate the antimicrobial efficacy of engineered multivalent nanoparticle systems based on silver or gold nanoparticles functionalized with UBI. Spectroscopy techniques demonstrated that NPs were functionalized with UBI mainly through interactions with the -NH2 groups. A significant increase in the antibacterial activity against Escherichia coli and Pseudomonas aeruginosa was obtained with the conjugate AgNP-UBI with regard to that of AgNP. No inhibition of bacterial growth was observed with AuNP and AuNP-UBI using a nanoparticle concentration of up to 182 μg mL−1. Nonetheless, silver nanoparticles conjugated to the UBI antimicrobial peptide may provide an alternative therapy for topical infections.

1 December 2020 in Drug Discovery Today
Verified
Journal Article
Closed access
AAAmirhossein Ahmadi
Amirhossein Ahmadi
SHSamira Hosseini-Nami
Samira Hosseini-Nami
ZAZiaeddin Abed
Ziaeddin Abed
JBJaber Beik
Jaber Beik
LALiliana Aranda-Lara
Liliana Aranda-Lara
ASAli Shakeri-Zadeh
Ali Shakeri-Zadeh